Bristol-Myers Squibb

Bristol-Myers Squibb

Yahoo Finance • 16 hours ago

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 17 hours ago

Bristol Myers Stock Tumbles on ‘Confounding’ Trial Results

Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028. Continue Reading... Full story

Yahoo Finance • yesterday

On the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' Initiative

More than 70 personalized 'Small Wins' toolkits, assembled by Bristol Myers Squibb employees, were designed to encourage everyday engagement, self-recognition and emotional well-being among people living with schizophrenia in Saudi Arabia.... Full story

Yahoo Finance • 2 days ago

Notable healthcare headlines for the week: Novavax, Moderna and Becton Dickinson in focus

Wall Street regained some momentum on Friday, after the AI trade came under pressure on Thursday. The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#source=url_first_level%3Amarket-news%7Csection%3Amarket-news%7Csection_asset%3Aful... Full story

Yahoo Finance • 3 days ago

Hospital group files lawsuit to stop 340B rebate pilot again

[An overturned pill bottle spills cash and medicinal capsules] Enrique Yocoyani Aguilar Licona/iStock via Getty Images The American Hospital Association has once again filed a lawsuit to halt a new pilot that tests a revised rebate model... Full story

Yahoo Finance • 5 days ago

Coca-Cola (KO) Posted 5% Volume Growth in Q2, Does Its Multiple Already Price It In?

A while ago Coca-Cola (NYSE:KO) reported a quarter where everything moved the right way at once: more cases sold, slightly higher prices, and a wider operating margin. The stock still trades above its own five-year average multiple. The c... Full story

Yahoo Finance • 5 days ago

More Than 100 Technology Leaders Registered for HMG Strategy's 19th Annual Greenwich C-Level Technology Leadership Summit on October 15

HMG Strategy Complimentary executive passes remain available for qualified CIOs, CISOs, CTOs, Chief Digital Officers, Chief AI Officers and other senior technology executives FAIRFIELD, Conn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- More than... Full story

Yahoo Finance • 8 days ago

CN Bio Announces Expert Speaker Line-Up and Scientific Program for Inaugural Organ-on-a-Chip e-Symposium

Four sessions across two days focusing on key drug discovery and development application areas oforgan-on-a-chip technologies Expert-led presentations and panel discussions featuring leaders across research, regulatory and industry, includ... Full story

Yahoo Finance • 8 days ago

3 Value Stocks We Steer Clear Of

3 Value Stocks We Steer Clear Of Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they're out of favor. The key risk, however, is that these stocks are usua... Full story

Yahoo Finance • 8 days ago

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

Second-Year Champions in Care Campaign Introduces $1 Million Community Grant Program for Medically Underserved Communities PRINCETON, NJ / ACCESS Newswire / October 5, 2026 / Originally published by Bristol Myers Squibb Bristol Myers Squ... Full story

Yahoo Finance • 9 days ago

AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?

AbbVie Inc. (NYSE:ABBV) closed at $262.82 on October 2, and Bristol Myers Squibb Company (NYSE:BMY) at $61.15. Both spent the last few years doing the same difficult thing. Replacing a drug that was about to lose its patent with something... Full story

Yahoo Finance • 10 days ago

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

The Trump administration has selected 10 companies, including AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]), Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]), Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), and GSK (GSK [http... Full story

Yahoo Finance • 13 days ago

Bristol wins approval of Camzyos for children with rare heart condition

[HCM acronym. Hypertrophic Cardiomyopathy concept] Alex Aviles * The US FDA has approved Bristol Myers Squibb's (BMY [https://seekingalpha.com/symbol/BMY]) Camzyos (mavacamten) for children with symptomatic obstructive hypertrophic card... Full story

Yahoo Finance • 13 days ago

Pharmaceutical industry lobbying group names new CEO, Eric Cantor

[Cantor And John Thune Hold Press Conference On Economy] Alex Wong/Getty Images News * The Pharmaceutical Research and Manufacturers of America (PhRMA) has selected former Republican House Majority Leader Eric Cantor as its next CEO and... Full story

Yahoo Finance • 13 days ago

CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J

Company Logo The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding c... Full story

Yahoo Finance • 14 days ago

AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck

Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech. Continue Reading... Full story

Yahoo Finance • 14 days ago

AstraZeneca Pays $2 Billion To Get Into High-Profile Cancer Space

Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech. Continue Reading... Full story

Yahoo Finance • 15 days ago

Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure?

On September 18, Novartis AG (NYSE:NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Cosentyx (secukinumab) to treat polymyalgia rheumatica... Full story

Yahoo Finance • 15 days ago

Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy

[Wall Street sign in Lower Manhattan, NYC] georgeclerk Cantor Fitzgerald initiated Lexicon Pharmaceuticals (LXRX [https://seekingalpha.com/symbol/LXRX]) at overweight, saying that it is optimistic on upcoming phase 3 data of the SGLT1/2 i... Full story

Yahoo Finance • 17 days ago

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid art... Full story